Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 2/20/2026 | $25.00 | Underweight | Barclays | |
| 2/12/2026 | $27.00 | Outperform → Neutral | Daiwa Securities | |
| 1/7/2026 | $25.00 | Neutral | UBS | |
| 12/16/2025 | $367.00 | Equal-Weight → Overweight | Morgan Stanley | |
| 12/12/2025 | $331.00 | Buy | Citigroup | |
| 12/2/2025 | $26.00 | Neutral | Citigroup | |
| 11/18/2025 | $290.00 | Neutral | BNP Paribas Exane | |
| 11/13/2025 | $30.00 | Sector Outperform | Scotiabank |
Barclays initiated coverage of Pfizer with a rating of Underweight and set a new price target of $25.00
Daiwa Securities downgraded Pfizer from Outperform to Neutral and set a new price target of $27.00
UBS resumed coverage of Pfizer with a rating of Neutral and set a new price target of $25.00
S-3ASR - L3HARRIS TECHNOLOGIES, INC. /DE/ (0000202058) (Filer)
13F-HR - PFIZER INC (0000078003) (Filer)
10-K - L3HARRIS TECHNOLOGIES, INC. /DE/ (0000202058) (Filer)
For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter
Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:
For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - L3HARRIS TECHNOLOGIES, INC. /DE/ (0000202058) (Issuer)
The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancer Pivotal results from the Phase 3 portion with mFOLFOX6 of the BREAKWATER trial demonstrated a clinically meaningful and statistically significant 51% risk reduction in death and a 47% risk reduction in disease progression or death compared to chemotherapy treatment with or without bevacizumab Expanded indication enables flexibility to use BRAFTOVI in combination with cetuximab and different fluorouracil-based chemotherapy regimens Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAF
VANCOUVER, British Columbia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The global commercial space launch market, valued at $8.2 billion in 2024, is projected to nearly quadruple to $31.9 billion by 2034 as small satellite demand accelerates[1]. Congress approved $839 billion in defense spending for fiscal 2026, including $4 billion for missile warning and tracking satellites and $13.4 billion to integrate space and missile defense systems[2]. Companies positioned at the intersection of commercial launch and national security include Starfighters Space (NYSE-A: FJET), Rocket Lab (NASDAQ:RKLB), L3Harris Technologies (NYSE:LHX), Intuitive Machines (NASDAQ:LUNR) and N
Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. About Pfizer: Breakthrough
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. About Pfizer: Breakthrough
Firm makes three additions to senior leadership team and elevates four to vice president AE Industrial Partners, LP ("AE Industrial" or the "Firm"), a private investment firm focused on technologies and services considered critical to aerospace and national and economic security, today announced its 2026 promotions, which included the elevation of Jon Lusczakoski to Partner, Matthew Friendly to General Counsel & Chief Compliance Officer, Tess Sprechman to Managing Director, Head of Investor Relations, and Megan LeFevre to Head of Human Resources. Additionally, Alyssa Goessler, Adrian Lee, Tucker Long, and Dave Paolantonio have been appointed Vice President. "2025 was a year of exception
Focused Execution Drives Strong Full-Year 2025 EPS Performance Enters 2026 with Clear Strategic Priorities and Growing Late-Stage Pipeline Advanced 11 Key Pivotal Study Starts in 2025 and ~20 Key Pivotal Study Starts Planned for 2026 Pfizer Inc. (NYSE:PFE) reported financial results for fourth-quarter and full-year 2025 and reaffirmed its full-year 2026 financial guidance(1) provided on December 16, 2025. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfizer's foundation for future growth. Looking ahead, 2026 will be an important year rich in key catalysts, inc
Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham
Voluntary agreement meets the President's four requests while also protecting the U.S. ecosystem responsible for America's leadership in delivering medical breakthroughs Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer's ability to expand investment in U.S.-based innovation and return manufacturing to the U.S. Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology Pfizer CEO Albert Bourla joins President Donald J. Trump and members of his Administration in White House event today Pfizer Inc. (NYSE:PFE) today announced a historic agreement with the T
Equity Insider News Commentary Issued on behalf of VisionWave Holdings, Inc. VANCOUVER, BC, Sept. 26, 2025 /PRNewswire/ -- Global military spending hit a record $2.7 trillion in 2024, marking a 9.4% surge that represents the steepest year-over-year increase in at least three decades as nations respond to "intensifying wars and rising geopolitical tensions worldwide," according to UN report[1]. NATO's updated defense expenditure data released in August confirms all 32 allies are expected to meet the 2% GDP spending target this year, while the alliance's commitment to reach 5% of GDP by 2035 creates unprecedented demand for advanced military technologies and platforms[2]. This defense spending
SC 13G/A - L3HARRIS TECHNOLOGIES, INC. /DE/ (0000202058) (Subject)
SC 13G/A - L3HARRIS TECHNOLOGIES, INC. /DE/ (0000202058) (Subject)
SC 13G/A - L3HARRIS TECHNOLOGIES, INC. /DE/ (0000202058) (Subject)